Meeting
2019 ASCO Annual Meeting
A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma (NCT02023710).
Authors
Xieqiao Yan
Peking University Cancer Hospital, Beijing, China
Xieqiao Yan , Xinan Sheng , Lu Si , Zhihong Chi , Chuanliang Cui , Siming Li , Lili Mao , BIN LIAN , Bixia Tang , Xuan Wang , Yan Kong , Jie Dai , Xiaoshi Zhang , Xin Song , Jun Guo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02023710
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9521)
DOI
10.1200/JCO.2019.37.15_suppl.9521
Abstract #
9521
Poster Bd #
92
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao
Poster
2023 ASCO Annual Meeting
Final results of a phase II trial of prolgolimab with platinum-based therapy and bevacizumab in patients with advanced cervical cancer.
First Author: Sergey Fogt
Poster
2023 ASCO Annual Meeting
A phase 2, open-label, multicenter study investigating efficacy and safety of RP3 oncolytic immunotherapy combined with other therapies in patients with locoregionally advanced or recurrent squamous cell carcinoma of the head and neck.
First Author: Kevin Joseph Harrington
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase II study of paclitaxel and carboplatin plus PD-1 inhibitors combined with anlotinib as first-line treatment for advanced esophageal cancer.
First Author: Mingfang Xu